Higher THC Doses Caused Greater Cognitive and Motor Impairment in a Dose-Dependent Pattern
In 24 non-daily cannabis users, cognitive and motor impairment increased linearly with THC dose up to 69 mg, with some individuals showing no motor impairment even at high blood THC levels.
Quick Facts
What This Study Found
Twenty-four non-daily male cannabis users smoked cannabis cigarettes containing 0, 29.3, 49.1, or 69.4 mg THC in a four-way crossover design.
Response time slowed linearly across all cognitive tasks (simple reaction time, visual-spatial attention, sustained attention, divided attention, and short-term memory) as THC dose increased. Motor control also worsened linearly with dose.
Errors increased significantly with higher doses in short-term memory and sustained attention tasks specifically.
However, some participants showed no motor impairment even at THC blood concentrations above 40 ng/mL, suggesting substantial individual variability in susceptibility to THC-induced impairment.
Key Numbers
24 participants, 2-9 joints per month. THC doses: 0, 29.3, 49.1, and 69.4 mg (up to 23% THC). Response time and motor impairment increased linearly with dose. Some participants showed no motor impairment even above 40 ng/mL blood THC.
How They Did This
Double-blind, placebo-controlled, randomized, four-way crossover study. 24 non-daily male cannabis users (2-9 joints/month) smoked cannabis cigarettes at four THC doses (0, 29.3, 49.1, 69.4 mg) on separate occasions. Cognitive tasks and motor control were assessed.
Why This Research Matters
With cannabis potency increasing, this study directly tested how high-THC products affect cognitive and motor function. The linear dose-response relationship and individual variability have implications for traffic safety and impairment testing.
The Bigger Picture
As cannabis potency has increased over the years, understanding dose-response relationships for impairment becomes more important. The finding that some individuals show no motor impairment at high blood levels complicates per se impairment standards for driving.
What This Study Doesn't Tell Us
Only 24 non-daily male users were studied. Experienced daily users might show different dose-response patterns due to tolerance. The controlled smoking protocol may not reflect real-world consumption. Individual variability was noted but not fully characterized.
Questions This Raises
- ?Why do some individuals resist motor impairment at high THC blood levels?
- ?Should impairment standards be based on THC blood levels if individual variability is this high?
- ?How do regular users differ in their dose-response curves?
Trust & Context
- Key Stat:
- Linear impairment increase up to 69 mg THC, but some showed no motor impairment above 40 ng/mL
- Evidence Grade:
- Well-designed four-way crossover RCT, though limited to 24 non-daily male users.
- Study Age:
- Published in 2009. Cannabis products today routinely exceed the potency levels tested in this study, making these findings even more relevant.
- Original Title:
- Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).
- Published In:
- Psychopharmacology, 204(1), 85-94 (2009)
- Authors:
- Hunault, Claudine C, Mensinga, Tjeert T, Böcker, Koen B E, Schipper, C Maarten A, Kruidenier, Maaike, Leenders, Marianne E C, de Vries, Irma, Meulenbelt, Jan
- Database ID:
- RTHC-00360
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Is 69 mg THC a lot?
Yes. At the time of this study, it represented a very high-potency cannabis cigarette (23% THC). Many commercial cannabis products today contain similar or even higher concentrations, which is why this dose-response data remains relevant.
Why did some people show no motor impairment at high blood THC levels?
Individual variation in THC sensitivity is not fully understood. Genetic differences in cannabinoid receptors, variations in THC metabolism, and prior exposure all likely contribute. This variability makes it difficult to set universal blood THC thresholds for impairment.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- does-weed-expire-shelf-life-potency
- how-to-store-weed-fresh-temperature-light
- how-to-store-edibles-shelf-life-potency
- what-is-dabbing-what-does-it-do-body
- what-are-moon-rocks-why-strong
- pulled-over-with-weed-in-car
- cannabis-dui-laws-impairment-testing-penalties
- thc-and-coordination-balance-motor-skills
- does-thc-affect-driving-impairment-science
Cite This Study
https://rethinkthc.com/research/RTHC-00360APA
Hunault, Claudine C; Mensinga, Tjeert T; Böcker, Koen B E; Schipper, C Maarten A; Kruidenier, Maaike; Leenders, Marianne E C; de Vries, Irma; Meulenbelt, Jan. (2009). Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).. Psychopharmacology, 204(1), 85-94. https://doi.org/10.1007/s00213-008-1440-0
MLA
Hunault, Claudine C, et al. "Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).." Psychopharmacology, 2009. https://doi.org/10.1007/s00213-008-1440-0
RethinkTHC
RethinkTHC Research Database. "Cognitive and psychomotor effects in males after smoking a c..." RTHC-00360. Retrieved from https://rethinkthc.com/research/hunault-2009-cognitive-and-psychomotor-effects
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.